Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: Data from LUMINA (LXXVI), a multi-ethnic us cohort

Clinical and Experimental Rheumatology

Volumn 32, Issue 2, 2014, Pages 162-167

  Willis, Rohan ^a   Seif, Alan M ^a   McGwin Jr , Gerald ^b   Martinez Martinez, Laura Aline ^a   González, Emilio B ^a   Doan, Ellis ^a   Dang, Neha ^a   Papalardo, Elizabeth ^a   Liu, Jigna ^b   Vilá, Luis M ^d   Reveille, John D ^c   Alarcón, Graciela S ^b   Pierangeli, Silvia S ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

Author keywords

Biomarkers of inflammation; Biomarkers of thrombosis; Lupus; Statins

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CD40 LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; NEPHELOMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; UNITED STATES; BLOOD ANALYSIS; DISEASE ASSOCIATION; LONGITUDINAL STUDY; SYSTEMIC LUPUS ACTIVITY MEASURE REVISED; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; ETHNIC GROUPS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKINS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PATIENT ACUITY; PUERTO RICO; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84904397645     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. KOTZIN BL: Systemic lupus erythematosus. Cell 1996; 85: 303-6.
2. LEE HM, SUGINO H, NISHIMOTO N: Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 676284.
3. DAVAS EM, TSIROGIANNI A, KAPPOU I et al.: Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999; 18: 17-22.
4. KATO K, SANTANA-SAHAGúN E, RASSENTI LZ et al.: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 947-55.
5. SMADJA D, GAUSSEM P, RONCAL C, FISCHER AM, EMMERICH J, DARNIGE L: Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus 2010; 19: 837-43.
6. GEARING AJ, HEMINGWAY I, PIGOTT R, HUGHES J, REES AJ, CASHMAN SJ: Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci 1992; 667: 324-31.
7. BAUER JW, PETRI M, BATLIWALLA FM et al.: Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098-107.
8. LINKER-ISRAELI M, DEANS RJ, WALLACE DJ, PREHN J, OZERI-CHEN T, KLINENBERG JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991; 147: 117-23.
9. GABAY C, CAKIR N, MORAL F et al.: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303-8.
10. DESAI-MEHTA A, LU L, RAMSEY-GOLDMAN R, DATTA SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-73.
11. McCLAIN MT, ARBUCKLE MR, HEINLEN LD et al.: The prevalence, onset and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1226-32.
12. CUADRADO MJ, BUENDíA P, VELASCO F et al.: Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006; 4: 2461-9.
13. VEGA-OSTERTAG M, CASPER K, SWERLICK R, FERRARA D, HARRIS EN, PIERANGELI SS: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545-54.
14. BERMAN J, GIRARDI G, SALMON JE: TNF-alpha is a critical effector and a target for therapy in Antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485-90.
15. DANESH FR, ANEL RL, ZENG L et al.: Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp 2003; 51: 139-48.
16. FERREIRA GA, NAVARRO TP, TELLES RW, ANDRADE LE, SATO EI: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007; 46: 1560-5.
17. SOUBRIER M, MATHIEU S, HERMET M et al.: Do all lupus patients need statins? Joint Bone Spine 2013; 80: 244-9.
18. TU H, LI Q, XIANG S et al.: Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role of regulatory T cells. Atherosclerosis 2012; 222: 29-33.
19. PIERANGELI SS, ERKAN D: Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 2010; 19: 475-85.
20. FERNáNDEZ M, McGWIN G, ANDRADE R et al.; For the LUMINA Group: Systemic Lupus Erythematosus in a Multiethnic US Cohort (LUMINA XLIX). Preliminary evaluation of the Impact of statins on disease activity. J Clin Rheumatol 2008; 14:178-180.
21. REVEILLE JD, MOULDS JM, AHN C et al.: Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA study group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1161-72.
22. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
23. PIERANGELI SS, HARRIS EN: A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc 2008; 3: 840-8.
24. GRIFFITHS B, MOSCA M, GORDON C: Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005; 19: 685-708.
25. MERONI PL, RASCHI E, TESTONI C et al.: Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870-8.
26. FERRARA DE, LIU X, ESPINOLA RG et al.: Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-9.
27. FERRARA DE, SWERLICK R, CASPER K et al.: Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2: 1558-63.
28. MARTíNEZ-MARTíNEZ LA, AMIGO MC, OROZCO A et al.: Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model. Clin Exp Rheumatol 2007; 25: 18-9.
29. JAJORIA P, MURTHY V, PAPALARDO E, ROMAY-PENABAD Z, GLEASON C, PIERANGELI SS: Statins for the treatment of antiphospholipid syndrome? Ann NY Acad Sci 2009; 1173: 736-45.
30. LóPEZ-PEDRERA C, RUIZ-LIMON P, AGUIRRE MA et al.: Global effects of fluvastatin on the prothrombotic status of patients with Antiphospholipid syndrome. Ann Rheum Dis 2011; 70: 675-82.
31. BARNES EV, NARAIN S, NARANJO A et al.: High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576-82.
32. AGMON-LEVIN N, MOSCA M, PETRI M, SHOENFELD Y: Systemic lupus erythematosus one disease or many? Autoimmun Rev 2012; 11: 593-5.
33. NOSSENT J, KISS E, ROZMAN B, POKORNY G et al.: Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-56.
34. SCHANBERG LE, SANDBORG C, BARNHART HX et al.: Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012; 64: 285-96.
35. PETRI MA, KIANI AN, POST W, CHRISTOPHER-STINE L, MAGDER LS: Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011; 70: 760-5.
36. MOK CC, WONG CK, TO CH, LAI JP, LAM CS: Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2011; 63: 875-83.